Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Zbysek Pavelek"'
Autor:
Dominika Stastna, Jiri Drahota, Michal Lauer, Aneta Mazouchova, Ingrid Menkyova, Jana Adamkova, Radek Ampapa, Michal Dufek, Marketa Grunermelova, Pavel Hradilek, Eva Kubala Havrdova, Jan Mares, Alena Martinkova, Zbysek Pavelek, Marek Peterka, Eva Recmanova, Petra Rockova, Ivana Stetkarova, Pavel Stourac, Marta Vachova, Dana Horakova
Publikováno v:
Biomedical Papers, Vol 168, Iss 3, Pp 262-270 (2024)
Aims. Multiple sclerosis treatment strategies are changing in the Czech Republic. According to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying therapies is increasing. In this survey, we describe the actual da
Externí odkaz:
https://doaj.org/article/031942c91d96488a818590beaafcebd7
Autor:
Pavel Potuznik, Jiri Drahota, Dana Horakova, Marek Peterka, Aneta Mazouchova, David Matyas, Zbysek Pavelek, Marta Vachova, Eva Recmanova, Ivana Stetkarova, Jana Libertinova, Jan Mares, Pavel Stourac, Marketa Grunermelova, Alena Martinkova, Jana Adamkova, Pavel Hradilek, Radek Ampapa, Michal Dufek, Eva Kubala Havrdova, Dominika Stastna
Publikováno v:
Journal of Central Nervous System Disease, Vol 16 (2024)
Background Cladribine, a selective immune reconstitution therapy, is approved for the treatment of adult patients with highly active multiple sclerosis (MS). Objectives Provide experience with cladribine therapy in a real-world setting. Methods This
Externí odkaz:
https://doaj.org/article/184f4c6999bb4bada8b072f3e0cb99d2
Autor:
Martin Valis, Alzbeta Dlabkova, Jakub Hort, Francesco Angelucci, Jaroslav Pejchal, Kamil Kuca, Zbysek Pavelek, Jana Zdarova Karasova, Michal Novotny
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 165, Iss , Pp 115226- (2023)
Externí odkaz:
https://doaj.org/article/e9d9c5fb4f944a3ab5793b47851d58ee
Autor:
Martin Valis, Alzbeta Dlabkova, Jakub Hort, Francesco Angelucci, Jaroslav Pejchal, Kamil Kuca, Zbysek Pavelek, Jana Zdarova Karasova, Michal Novotny
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 159, Iss , Pp 114223- (2023)
Background: The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. Methods: Forty AD patients receiving 10 mg/day of donepezil w
Externí odkaz:
https://doaj.org/article/9493af4d107e474493dfe188b7444fcc
Autor:
Zbysek Pavelek, Ondrej Soucek, Jan Krejsek, Ilona Sejkorova, Oldrich Vysata, Blanka Klimová, Francesco Angelucci, Pavel Stourac, Martin Valis, Marek Peterka, Lukáš Sobisek, Michal Novotny
Publikováno v:
Journal of Immunology Research, Vol 2023 (2023)
Background. The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms
Externí odkaz:
https://doaj.org/article/681588e3d4a84d559d0b5dd4548066b2
Autor:
Martin Valis, David Herman, Nela Vanova, Jiri Masopust, Oldrich Vysata, Jakub Hort, Zbysek Pavelek, Blanka Klimova, Kamil Kuca, Jan Misik, Jana Zdarova Karasova
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Memantine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist utilized as a palliative cure for Alzheimer’s disease. This is the second study examining the memantine concentrations in cerebrospinal fluid. The previously published st
Externí odkaz:
https://doaj.org/article/eadf77827c654fb3b821b45dd8aee3ef
Autor:
Dominika Stastna, Jiri Drahota, Michal Lauer, Aneta Mazouchova, Ingrid Menkyova, Jana Adamkova, Radek Ampapa, Michal Dufek, Marketa Grunermelova, Pavel Hradilek, Eva Kubala Havrdova, Jan Mares, Alena Martinkova, Zbysek Pavelek, Marek Peterka, Eva Recmanova, Petra Rockova, Ivana Stetkarova, Pavel Stourac, Marta Vachova, Dana Horakova
Publikováno v:
Biomedical Papers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62d9b808a73096fe9bcc9fa9bcf3d568
https://doi.org/10.5507/bp.2023.015
https://doi.org/10.5507/bp.2023.015
Autor:
Martin Vališ, Anat Achiron, Hans Peter Hartung, Jan Mareš, Veronika Tichá, Pavel Štourač, Simona Halusková, Francesco Angelucci, Zbyšek Pavelek
Publikováno v:
Drugs in R&D, Vol 23, Iss 4, Pp 331-338 (2023)
Abstract Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medi
Externí odkaz:
https://doaj.org/article/7ae609d3e2254eba86eb7e8f90c19741
Autor:
Ilona Součková, Ondřej Souček, Jan Krejsek, Oldřich Vyšata, David Matyáš, Marek Peterka, Michal Novotný, Pavel Kunc, Zbyšek Pavelek
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2179 (2024)
The aim of this study was to conduct QuantiFERON Monitor (QFM) testing in patients with multiple sclerosis (MS), which is used to monitor the state of the immune system through the non-specific stimulation of leukocytes followed by determining the le
Externí odkaz:
https://doaj.org/article/dd95da90c19c46ac82468c8c011e3116
Autor:
Martin Vališ, Zbyšek Pavelek, Michal Novotný, Blanka Klímová, Jana Šarláková, Simona Halúsková, Marek Peterka, Ivana Štětkárová, Pavel Štourač, Jan Mareš, Pavel Hradílek, Radek Ampapa, Marta Vachová, Eva Recmanová, Eva Meluzínová
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
ImportanceMultiple sclerosis can also affect children. Approximately 3–10% of patients develop multiple sclerosis before the age of 16.ObjectiveThe aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosi
Externí odkaz:
https://doaj.org/article/d9ce93a6892340cf87ef140dd44f18d7